Acetyl-TP73 (K321) Antibody

What is TP73 and what functional roles does it play in cellular biology?

TP73 (Tumor protein p73) is a member of the p53 family of transcription factors and plays critical roles in multiple cellular processes. It functions as a p53-like transcription factor involved in cell cycle regulation, DNA damage response, and apoptosis . TP73 has also been implicated in neurogenesis, immune regulation, and ciliary function .

The gene produces multiple isoforms through alternative splicing and alternative promoter usage, leading to functionally distinct proteins that can have either tumor-suppressive (TAp73) or oncogenic (ΔNp73) activities . Research has demonstrated that TP73 is involved in the pathogenesis of various cancers, including adult T-cell leukemia/lymphoma (ATL), where it is regulated by an intragenic super-enhancer .

What is the significance of TP73 acetylation at lysine 321?

Acetylation at lysine 321 (K321) represents a critical post-translational modification that regulates TP73 function. This specific modification:

• Alters the transcriptional activity of TP73, affecting its ability to regulate target genes

• Influences protein-protein interactions with transcriptional co-factors

• Modulates TP73 stability and subcellular localization

• May serve as a regulatory switch between different TP73 functions

Detecting this specific acetylation site provides researchers with crucial information about the activation status and functional state of TP73 in various cellular contexts and disease models . The Acetyl-TP73 (K321) antibody specifically recognizes this post-translational modification, making it valuable for investigating the regulation of TP73 activity .

What are the recommended applications and protocols for using Acetyl-TP73 (K321) Antibody?

The Acetyl-TP73 (K321) Antibody has been validated for several research applications:

Western Blotting (WB):

• Recommended dilution: 1:500-1:2000

• Sample preparation: Standard protein extraction using RIPA or NP-40 lysis buffers containing protease inhibitors and deacetylase inhibitors (e.g., trichostatin A, nicotinamide)

• Loading control: Consider using total TP73 antibody on parallel blots to normalize acetylation levels

ELISA:

• Recommended dilution: 1:20000

• Particularly useful for quantitative measurement of K321 acetylation levels

Immunohistochemistry (IHC):

• Works with paraffin-embedded sections (IHC-p)

• Antigen retrieval methods should be optimized based on tissue type

Immunofluorescence (IF):

• Has been used to study TP73 localization in relation to its acetylation status

• Can be combined with other markers to study TP73's role in ciliary function

The antibody specifically detects endogenous levels of p73 protein only when acetylated at K321, making it valuable for studying this specific post-translational modification .

What are the optimal storage and handling conditions for Acetyl-TP73 (K321) Antibody?

For maintaining optimal antibody activity:

Storage conditions:

• Upon receipt, store at -20°C or -80°C

• Avoid repeated freeze-thaw cycles that can degrade antibody quality

• When shipped, the antibody is typically transported at 4°C

Working solution preparation:

• The antibody is provided as a liquid in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide

• This formulation helps maintain stability during storage

• For long-term use, consider preparing small aliquots to minimize freeze-thaw cycles

Handling recommendations:

• Before use, gently mix without vortexing to avoid protein denaturation

• Brief centrifugation is recommended if droplets are observed on the vial walls

• Working dilutions should be prepared just before use and are typically not recommended for storage

How should experimental controls be designed when using Acetyl-TP73 (K321) Antibody?

Designing appropriate controls is crucial for interpreting results obtained with the Acetyl-TP73 (K321) Antibody:

Positive controls:

Negative controls:

• Samples treated with deacetylases to remove the acetyl group from K321

• Cells with TP73 knockdown or knockout (for antibody specificity validation)

• Use of blocking peptide (the immunizing peptide) to confirm signal specificity

Experimental validation:

• Comparison with total TP73 antibody to distinguish changes in acetylation from changes in total protein expression

• Comparing acetylation levels between experimental conditions (e.g., treated vs. untreated, normal vs. cancer cells)

• Testing multiple antibody dilutions to optimize signal-to-noise ratio

How can Acetyl-TP73 (K321) Antibody be used to study TP73's role in cancer pathogenesis?

The Acetyl-TP73 (K321) Antibody serves as a powerful tool for investigating TP73's involvement in cancer development and progression:

Differential acetylation analysis:

• Compare acetylation levels between normal and cancer tissues/cells

• Analyze changes in K321 acetylation during cancer progression stages

• Correlate acetylation patterns with clinical outcomes in patient samples

Functional studies in ATL:

• TP73 has been specifically implicated in adult T-cell leukemia/lymphoma (ATL) pathogenesis

• Research has shown that TP73 structural variants (SVs) with deletion of exons 2-3 confer a competitive advantage to ATL cells

• The antibody can help determine if acetylation at K321 is altered in cells with these SVs

Transcriptional regulation studies:

• Acetylation at K321 may influence TP73's transcriptional activity

• ChIP assays using this antibody can identify genomic targets regulated by acetylated TP73

• Gene expression analysis following modulation of K321 acetylation can reveal downstream pathways

Research findings in ATL patients:

• Studies have shown that TP73 SVs are associated with worse prognosis in ATL patients receiving mogamulizumab-containing treatment

• Cells with TP73 SVs exhibit gene expression profiles associated with enhanced resistance to apoptosis and growth advantage

• The acetylation status at K321 may provide additional insights into these altered functions

What methodologies can be employed to study the relationship between TP73 acetylation and its structural variants?

Investigating the interplay between TP73 acetylation and its structural variants requires integrated approaches:

Molecular characterization techniques:

• PCR-based assays to detect TP73 SVs (exons 2 or 2-3 deletion)

• Multiple software programs (DeviCNV, Manta, GRIDSS2) can be used to evaluate TP73 SVs from exome datasets

• Manual investigation of sequence data to confirm SV presence

Expression analysis:

• RNA-sequencing to analyze transcriptome profiles in samples stratified by TP73 SV status

• Quantitative assessment of TP73 and TP73-AS3 expression levels

• Analysis of downstream target genes affected by both TP73 SVs and acetylation status

Integrated approach workflow:

• Genomic characterization to identify TP73 SVs

• Western blotting with Acetyl-TP73 (K321) Antibody to assess acetylation levels

• Correlation analysis between SV status and acetylation patterns

• Functional studies to determine the impact of both variables on cellular phenotypes

Clinical correlation studies:

How can Acetyl-TP73 (K321) Antibody be used to study ciliary function and mucociliary clearance?

TP73 plays a critical role in ciliary development and function, with important implications for respiratory health:

Ciliary structure analysis:

• TP73 mutations have been linked to impaired mucociliary clearance

• The Acetyl-TP73 (K321) Antibody can be used alongside antibodies against acetylated α-tubulin to analyze cilia structure and length

• Immunofluorescence studies have confirmed that ciliary length is significantly reduced in TP73 mutant cells

In vitro ciliogenesis experiments:

• Respiratory epithelial cells obtained by nasal brush biopsy can be cultured as spheroids

• Immunofluorescence microscopy using antibodies against acetylated α-tubulin can confirm defects in multiciliated cell (MCC) differentiation

• The role of TP73 acetylation at K321 in this process can be investigated using the specific antibody

Transmission electron microscopy (TEM) integration:

• TEM analysis of respiratory cells reveals that TP73 mutant cilia appear stubby and reduced in length

• Combining TEM structural data with acetylation status can provide insights into how post-translational modifications affect ciliary ultrastructure

Air-liquid interface (ALI) culture system:

• Fully differentiated respiratory cells cultured at the air-liquid interface provide an excellent model system

• The Acetyl-TP73 (K321) Antibody can be used to track acetylation levels during ciliogenesis and in response to various stimuli

• These studies can help determine if acetylation at K321 is required for proper cilia formation and function

What are the technical considerations for validating Acetyl-TP73 (K321) Antibody specificity?

Ensuring antibody specificity is crucial for obtaining reliable results in TP73 acetylation studies:

Epitope-specific validation:

• The antibody was generated using a synthesized peptide derived from human p73 around the acetylation site of K321

• Performing peptide competition assays with the immunizing peptide can confirm binding specificity

• Testing with acetylated vs. non-acetylated peptides can verify modification specificity

Cross-reactivity assessment:

• Though the antibody is designed to be specific for human TP73 acetylated at K321, potential cross-reactivity with other p53 family members should be evaluated

• Testing in samples with knocked-down TP73 expression can confirm signal specificity

• Parallel testing with antibodies against acetylated p53 (e.g., Acetyl-P53 at Lys382) can help identify any cross-reactivity issues

Cellular model validation:

• Treatment with histone deacetylase inhibitors should increase the signal

• Treatment with deacetylases should decrease the signal

• Site-directed mutagenesis of K321 to arginine (which cannot be acetylated) should eliminate the signal

Western blot optimization:

• Molecular weight verification (expected at approximately 73 kDa)

• Testing multiple antibody dilutions (1:500-1:2000) to determine optimal signal-to-noise ratio

• Including appropriate controls such as immunoprecipitated TP73 protein

How can TP73 acetylation patterns be correlated with transcriptional activity using multi-omics approaches?

Integrating Acetyl-TP73 (K321) Antibody data with multi-omics approaches provides comprehensive insights into TP73 function:

ChIP-seq methodology:

• Chromatin immunoprecipitation using Acetyl-TP73 (K321) Antibody followed by sequencing

• Identifies genomic binding sites of acetylated TP73

• Comparison with binding sites of total TP73 to determine acetylation-specific targets

Integration with transcriptome data:

• RNA-seq analysis following modulation of TP73 acetylation

• Correlation between binding sites of acetylated TP73 and gene expression changes

• Studies have shown that patients with TP73 SVs have distinctive gene expression patterns that may be influenced by acetylation status

Proteome interaction studies:

• Immunoprecipitation with Acetyl-TP73 (K321) Antibody followed by mass spectrometry

• Identifies protein interaction partners specific to acetylated TP73

• Comparison with interactome of non-acetylated TP73

Experimental workflow:

• ChIP-seq with Acetyl-TP73 (K321) Antibody to identify genomic binding sites

• RNA-seq to determine transcriptional changes

• Proteomics to identify interaction partners

• Integration of these datasets to build comprehensive regulatory networks

This multi-omics approach has revealed that ATL cells with TP73 SVs exhibit altered expression of genes associated with apoptosis resistance and growth advantage, which may be influenced by changes in TP73 acetylation patterns .

How has Acetyl-TP73 (K321) Antibody been used in cancer research?

The antibody has been instrumental in several cancer research applications, particularly in studying adult T-cell leukemia/lymphoma (ATL):

Prognostic marker development:

• Studies have demonstrated that TP73 structural variants are associated with worse prognosis in ATL patients

• Western blot analysis using the Acetyl-TP73 (K321) Antibody in K562 cells has provided insights into leukemia cell biology

• The acetylation status of TP73 may serve as a potential prognostic biomarker in conjunction with structural variant analysis

Therapeutic response prediction:

• ATL patients with TP73 SVs showed poor responses to mogamulizumab-containing treatment

• Acetylation at K321 may influence this therapeutic response

• Monitoring acetylation patterns could potentially help predict treatment outcomes

Molecular pathway analysis:

• TP73 expression influences multiple downstream genes (RAB26, FER1L4, DAB2, ARL11, PTK6, TCAE3)

• The acetylation status of TP73 at K321 may regulate its ability to modulate these genes

• Gene expression analysis in combination with acetylation studies provides insights into the molecular mechanisms underlying cancer progression

What techniques can be combined with Acetyl-TP73 (K321) Antibody to study gene regulation mechanisms?

Multiple advanced techniques can be integrated with this antibody to elucidate TP73's gene regulatory functions:

ChIP-seq protocol optimization:

• Crosslink cells with formaldehyde to preserve protein-DNA interactions

• Lyse cells and sonicate to shear chromatin

• Immunoprecipitate with Acetyl-TP73 (K321) Antibody (typically 5-10 μg per IP)

• Reverse crosslinks and purify DNA

• Prepare libraries for next-generation sequencing

• Analyze data to identify genomic binding regions

Reporter assay integration:

• Clone TP73 target promoters identified by ChIP-seq into luciferase reporter constructs

• Co-transfect with wild-type TP73, acetylation-mimetic (K321Q), and acetylation-deficient (K321R) mutants

• Measure transcriptional activity and correlate with acetylation status

CRISPR-based approaches:

• Generate K321R mutations in endogenous TP73 to prevent acetylation

• Create K321Q mutations to mimic constitutive acetylation

• Compare transcriptional effects of these modifications using RNA-seq or targeted gene expression analysis

Typical findings:
Researchers have observed that TP73 SVs influence the expression of genes associated with tumor progression, such as ABLIM1 and LZTS2, whose expression was lower in primary ATL cells with SVs than without. These expression patterns may be further regulated by the acetylation status of TP73 .

How can experimental designs be optimized when studying acetylation dynamics of TP73?

Studying the dynamic nature of TP73 acetylation requires carefully designed experimental approaches:

Time-course experiments:

• Treat cells with acetylation inducers (HDAC inhibitors) or stress stimuli (DNA damage)

• Collect samples at multiple time points (0, 15, 30, 60, 120, 240 minutes)

• Analyze acetylation at K321 using Western blotting with the Acetyl-TP73 (K321) Antibody

• Compare with total TP73 levels and activity of relevant acetyltransferases/deacetylases

Acetylation enzyme manipulation:

• Overexpress or knock down specific acetyltransferases (e.g., p300, CBP) or deacetylases (e.g., SIRT1, HDAC1)

• Measure changes in K321 acetylation

• Correlate with alterations in TP73 transcriptional activity and target gene expression

Stimulus-dependent acetylation analysis:

This systematic approach provides insights into how various cellular stresses and signaling pathways regulate TP73 acetylation dynamics .

What are the considerations when using Acetyl-TP73 (K321) Antibody in comparative studies of normal versus disease states?

When comparing normal and disease tissues/cells, several important factors must be considered:

Sample preparation standardization:

• Consistent fixation protocols for tissues (timing, reagents, temperature)

• Standardized protein extraction methods for cells and tissues

• Inclusion of deacetylase inhibitors in lysis buffers to preserve acetylation status

• Quantitative loading controls for Western blot normalization

Tissue-specific considerations:

• Different tissues may have varying baseline levels of TP73 expression and acetylation

• Background signal may differ between tissue types

• Optimization of antibody concentration for each tissue type is recommended

Disease context analysis:

• In ATL research, TP73 structural variants influence disease progression

• The relationship between these variants and K321 acetylation requires careful analysis

• Controls should include both healthy individuals and disease patients without the specific molecular alteration being studied

Quantification methods:

• Use digital image analysis software for objective quantification

• Employ multiple technical and biological replicates

• Calculate relative acetylation levels (acetylated/total protein ratio)

• Consider the heterogeneity within samples when interpreting results

Research has shown significant differences in TP73 expression patterns between normal cells and ATL cells, with TP73 SVs associated with enhanced resistance to apoptosis and growth advantage. The acetylation status at K321 may contribute to these altered functions .

What are common issues encountered when using Acetyl-TP73 (K321) Antibody and how can they be resolved?

Researchers may encounter several challenges when working with this antibody:

Weak or absent signal:

• Increase antibody concentration (try 1:500 instead of 1:2000)

• Extend primary antibody incubation time (overnight at 4°C)

• Ensure protein acetylation is preserved by adding deacetylase inhibitors to lysis buffer

• Consider signal enhancement systems for low abundance targets

• Check if target protein is expressed in your sample type

High background or non-specific bands:

• Dilute primary antibody further (try 1:2000 instead of 1:500)

• Increase blocking time and/or blocking reagent concentration

• Use more stringent washing conditions (increase wash time or detergent concentration)

• Pre-adsorb antibody with non-specific proteins

• Use alternative blocking agents (switch between BSA, milk, or commercial blockers)

Inconsistent results between experiments:

• Standardize protein extraction and handling procedures

• Prepare fresh working dilutions for each experiment

• Store antibody as recommended to maintain stability

• Use consistent lot numbers for critical experiments

• Implement more rigorous positive and negative controls

How can the detection sensitivity of Acetyl-TP73 (K321) be enhanced for low-abundance samples?

Several approaches can improve detection of low levels of acetylated TP73:

Sample enrichment strategies:

Signal amplification methods:

• Use highly sensitive ECL substrates for Western blotting

• Employ biotin-streptavidin amplification systems

• Consider tyramide signal amplification for immunohistochemistry

• Use fluorescent secondary antibodies with longer exposure times for weak signals

Protocol optimization:

• Extended primary antibody incubation (overnight at 4°C)

• Increased protein loading (while maintaining good resolution)

• Reduced membrane pore size for Western blotting (PVDF with 0.2 μm instead of 0.45 μm)

• Enhanced antigen retrieval for fixed tissues

What methodological approaches can distinguish between different TP73 isoforms when studying K321 acetylation?

Differentiating between TP73 isoforms while analyzing K321 acetylation requires specialized techniques:

Isoform-specific detection strategy:

• Use isoform-specific antibodies (targeting TAp73 or ΔNp73) for immunoprecipitation

• Perform Western blotting with Acetyl-TP73 (K321) Antibody on the immunoprecipitated material

• This sequential approach allows assessment of acetylation levels on specific isoforms

Molecular weight differentiation:

• TAp73 isoforms typically run at ~75-80 kDa

• ΔNp73 isoforms typically run at ~65-70 kDa

• Use high-resolution gels (8-10% acrylamide) with extended run times to separate isoforms

• Include isoform-specific positive controls

RT-PCR integration:

• Perform RT-PCR to quantify expression levels of different TP73 transcript variants

• Correlate transcript abundance with protein acetylation patterns

• Consider the possibility that acetylation may affect isoform stability differently

Enhanced visualization techniques:

These approaches allow researchers to determine whether K321 acetylation differentially affects specific TP73 isoforms .

What emerging technologies could enhance the study of TP73 acetylation beyond current antibody-based approaches?

Several cutting-edge technologies show promise for advancing TP73 acetylation research:

Mass spectrometry-based approaches:

• Targeted MS can quantify site-specific acetylation with high precision

• Parallel reaction monitoring (PRM) enables simultaneous quantification of multiple acetylation sites

• SILAC or TMT labeling allows comparative analysis across multiple conditions

• These methods can detect acetylation at K321 along with other modifications on the same TP73 molecule

Proximity ligation assays (PLA):

• Combines antibody recognition with DNA amplification for enhanced sensitivity

• Can detect protein-protein interactions influenced by K321 acetylation

• Provides spatial information about acetylated TP73 within the cell

• Could reveal acetylation-dependent TP73 interaction networks

CRISPR-based acetylation reporters:

• Fusion of catalytically dead Cas9 with acetylation reader domains

• Target to TP73 locus to monitor acetylation in real-time

• Enables live-cell imaging of acetylation dynamics

• Could track K321 acetylation in response to various stimuli

Single-cell analysis:

• scRNA-seq combined with antibody-based protein detection

• Reveals heterogeneity in TP73 acetylation within cell populations

• Could identify rare cell populations with unique TP73 regulation

• Particularly relevant for cancer studies where cellular heterogeneity is important

How might TP73 acetylation research contribute to therapeutic development for conditions like ATL?

Understanding TP73 acetylation could lead to novel therapeutic strategies:

Targeted therapies based on TP73 acetylation status:

• HDAC inhibitors that specifically modulate TP73 acetylation

• Small molecules that bind to acetylated TP73 and alter its function

• Peptide mimetics that interact with acetylation-dependent protein binding sites

• These approaches could be particularly relevant for ATL patients with TP73 SVs who show poor response to current therapies

Biomarker development:

• TP73 SVs are associated with worse prognosis in ATL patients

• K321 acetylation status could serve as an additional prognostic marker

• Combined analysis of genetic variants and acetylation patterns may better predict treatment response

• Could guide personalized treatment decisions for ATL patients

Combination therapy strategies:

• Targeting TP73 acetylation in combination with conventional chemotherapy

• Modulating both TP73 and p53 family acetylation simultaneously

• Combining acetylation modulators with agents targeting downstream effectors

• Could overcome resistance mechanisms in aggressive ATL cases

Potential therapeutic targets identified from TP73 research:

• RAB26 and FER1L4 (upregulated in patients with TP73 SVs)

• ABLIM1 and LZTS2 (downregulated in patients with TP73 SVs)

• Targeting these pathways might counteract the effects of aberrant TP73 function

What research gaps remain in understanding the functional significance of TP73 K321 acetylation?

Despite progress, several important questions remain unanswered:

Acetylation writer and eraser enzymes:

• Which specific acetyltransferases modify TP73 at K321?

• Which deacetylases remove this modification?

• How are these enzymes regulated in different cellular contexts?

• Identifying these enzymes would provide potential therapeutic targets

Acetylation-dependent interactome:

• What proteins specifically interact with TP73 when acetylated at K321?

• How does this differ from interactions with non-acetylated TP73?

• Are there acetylation-specific reader proteins that recognize this modification?

• Answering these questions would clarify the functional consequences of K321 acetylation

Crosstalk with other modifications:

• How does K321 acetylation influence other post-translational modifications on TP73?

• Is there sequential or combinatorial modification of different sites?

• Does phosphorylation precede or follow acetylation?

• Understanding this crosstalk would provide a more complete picture of TP73 regulation

Tissue and context specificity:

• Does the significance of K321 acetylation vary across different tissues?

• How is acetylation regulated during development versus disease states?

• Are there cell type-specific effects of this modification?

• These insights would help target therapeutic interventions more precisely